ECSP12012343A - Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino - Google Patents

Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Info

Publication number
ECSP12012343A
ECSP12012343A ECSP12012343A ECSP12012343A EC SP12012343 A ECSP12012343 A EC SP12012343A EC SP12012343 A ECSP12012343 A EC SP12012343A EC SP12012343 A ECSP12012343 A EC SP12012343A
Authority
EC
Ecuador
Prior art keywords
derivative
ombrabulina
taxan
platinum
combination
Prior art date
Application number
Other languages
English (en)
Inventor
Patrick Cohen
Ileana Corina Oprea
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305653A external-priority patent/EP2397135A1/en
Priority claimed from EP10306256A external-priority patent/EP2481404A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP12012343A publication Critical patent/ECSP12012343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino y a su uso en el tratamiento de tumores sólidos avanzados.
ECSP12012343 2010-06-18 2012-12-18 Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino ECSP12012343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305653A EP2397135A1 (en) 2010-06-18 2010-06-18 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP10306256A EP2481404A1 (en) 2010-11-15 2010-11-15 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative

Publications (1)

Publication Number Publication Date
ECSP12012343A true ECSP12012343A (es) 2012-12-28

Family

ID=45347705

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012343 ECSP12012343A (es) 2010-06-18 2012-12-18 Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Country Status (22)

Country Link
US (1) US20130122113A1 (es)
EP (1) EP2582369A1 (es)
JP (1) JP2013528644A (es)
KR (1) KR20130088753A (es)
CN (1) CN103140224A (es)
AR (1) AR082005A1 (es)
AU (1) AU2011266635A1 (es)
BR (1) BR112012031917A2 (es)
CA (1) CA2802974A1 (es)
CO (1) CO6650420A2 (es)
DO (1) DOP2012000305A (es)
EA (1) EA201291268A1 (es)
EC (1) ECSP12012343A (es)
MA (1) MA34380B1 (es)
MX (1) MX2012014732A (es)
NI (1) NI201200183A (es)
PE (1) PE20130312A1 (es)
SG (1) SG186376A1 (es)
TN (1) TN2012000552A1 (es)
TW (1) TW201206419A (es)
UY (1) UY33457A (es)
WO (1) WO2011158206A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
WO2011158206A1 (en) 2011-12-22
AR082005A1 (es) 2012-11-07
EA201291268A1 (ru) 2013-04-30
TN2012000552A1 (en) 2014-04-01
CO6650420A2 (es) 2013-04-15
PE20130312A1 (es) 2013-03-26
KR20130088753A (ko) 2013-08-08
JP2013528644A (ja) 2013-07-11
NI201200183A (es) 2013-05-13
EP2582369A1 (en) 2013-04-24
DOP2012000305A (es) 2013-01-31
UY33457A (es) 2012-01-31
AU2011266635A1 (en) 2013-01-10
SG186376A1 (en) 2013-01-30
TW201206419A (en) 2012-02-16
MA34380B1 (fr) 2013-07-03
BR112012031917A2 (pt) 2017-11-28
US20130122113A1 (en) 2013-05-16
CN103140224A (zh) 2013-06-05
CA2802974A1 (en) 2011-12-22
MX2012014732A (es) 2013-01-22

Similar Documents

Publication Publication Date Title
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
CL2015000829A1 (es) Inhibidores de histona desmetilasas
EA201171367A1 (ru) Винилиндазолильные соединения
UA107822C2 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
IN2012DN06714A (es)
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
CR20110553A (es) Terapia complementaria contra el cáncer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CR20110573A (es) Combinacion antitumoral que comprende ave8062 y sorafenib
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
ECSP12012343A (es) Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino
MX2013008559A (es) Derivados de leptina.
CL2012000355A1 (es) Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc.
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
RU2009110124A (ru) Антигельминтное средство для лечения кабанов
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
BRPI0923349A2 (pt) Combinação antitumoral que associa o ave8062 e o docetaxel.